 Bio-Path Holdings, Inc., BPTH, a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces the presentation of a poster highlighting the clinical trial design of its Phase 1 study of BP1002 at the 2020 American Association for Cancer Research AACR Annual Meeting being held virtually from April 27-28, 2020. The poster, titled, A Phase I Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1002 L-Bcl-2 Antisense Oligonucleotide in Patients with Advanced Lymphoid Malignancies, was presented virtually by Dr. Ana Tari Ashizawa, Senior Vice President of Research, Development and Clinical Design at Bio-Path Holdings. 